Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progesterone receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    265 result(s) found for: Progesterone receptor. Displaying page 14 of 14.
    «« First « Previous 6  7  8  9  10  11  12  13  14 
    EudraCT Number: 2018-004165-13 Sponsor Protocol Number: IJB-LBC-NEOCHECKRAY-2018 Start Date*: 2019-06-06
    Sponsor Name:Institut Jules Bordet
    Full Title: Neo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab in luminal B breast cancer: a phase ll randomized trial
    Medical condition: Luminal B Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002994-39 Sponsor Protocol Number: Cx611-0204 Start Date*: 2016-04-06
    Sponsor Name:TIGENIX, S.A.U.
    Full Title: A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for...
    Medical condition: Severe community-acquired bacterial pneumonia requiring mechanical ventilation and/or vasopressors.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) LT (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000625-12 Sponsor Protocol Number: CTMX-M-2009-001 Start Date*: 2018-02-15
    Sponsor Name:CytomX Therapeutics, Inc
    Full Title: A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Lo...
    Medical condition: Metastatic or locally advanced unresectable solid tumors in following indications: breast cancer (BC), castrate-resistant prostate carcinoma (CRPC), non-small cell lung carcinoma (NSCLC), ovarian...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000048-73 Sponsor Protocol Number: AMT-101-201 Start Date*: 2020-09-24
    Sponsor Name:Applied Molecular Transport Inc.
    Full Title: A Combined Phase 2/3 12-week, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of AMT-101 in Subjects with Chronic Antibiotic-resistant Pouchitis
    Medical condition: Pouchitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10036463 Pouchitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002633-20 Sponsor Protocol Number: A4M105038 Start Date*: 2006-11-17
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice dail...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FI (Completed) FR (Completed) AT (Completed) IT (Completed) LT (Prematurely Ended) GB (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 6  7  8  9  10  11  12  13  14 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 11:31:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA